IL115059A - Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound - Google Patents

Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound

Info

Publication number
IL115059A
IL115059A IL11505995A IL11505995A IL115059A IL 115059 A IL115059 A IL 115059A IL 11505995 A IL11505995 A IL 11505995A IL 11505995 A IL11505995 A IL 11505995A IL 115059 A IL115059 A IL 115059A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
pct
combination
ramipril
oral administration
Prior art date
Application number
IL11505995A
Other languages
English (en)
Other versions
IL115059A0 (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9402924A external-priority patent/SE9402924D0/xx
Priority claimed from SE9402925A external-priority patent/SE9402925D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL115059A0 publication Critical patent/IL115059A0/xx
Publication of IL115059A publication Critical patent/IL115059A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IL11505995A 1994-09-02 1995-08-24 Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound IL115059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402924A SE9402924D0 (sv) 1994-09-02 1994-09-02 Novel pharmaceutical composition
SE9402925A SE9402925D0 (sv) 1994-09-02 1994-09-02 Novel oral pharmaceutical composition

Publications (2)

Publication Number Publication Date
IL115059A0 IL115059A0 (en) 1996-01-19
IL115059A true IL115059A (en) 2003-10-31

Family

ID=26662130

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11505995A IL115059A (en) 1994-09-02 1995-08-24 Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound

Country Status (33)

Country Link
US (1) US6086919A (sk)
EP (1) EP0726766B1 (sk)
JP (1) JP3776931B2 (sk)
KR (1) KR100438133B1 (sk)
CN (1) CN1134665A (sk)
AT (1) ATE217187T1 (sk)
AU (1) AU695865B2 (sk)
CA (1) CA2174338C (sk)
CZ (1) CZ292224B6 (sk)
DE (2) DE726766T1 (sk)
DK (1) DK0726766T3 (sk)
EE (1) EE03550B1 (sk)
EG (1) EG24435A (sk)
ES (1) ES2091173T3 (sk)
FI (1) FI117616B (sk)
GR (1) GR960300055T1 (sk)
HK (1) HK1001811A1 (sk)
HU (1) HU226894B1 (sk)
IL (1) IL115059A (sk)
IS (1) IS1781B (sk)
MX (1) MX9601586A (sk)
MY (1) MY119489A (sk)
NO (1) NO308694B1 (sk)
NZ (2) NZ292298A (sk)
PL (1) PL186745B1 (sk)
PT (1) PT726766E (sk)
RU (1) RU2184563C2 (sk)
SA (1) SA95160287B1 (sk)
SI (1) SI0726766T1 (sk)
SK (1) SK283633B6 (sk)
TR (1) TR199501077A2 (sk)
TW (1) TW483763B (sk)
WO (1) WO1996007400A1 (sk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19715594A1 (de) 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
KR100356374B1 (ko) * 2000-09-14 2002-10-19 사회복지법인삼성생명공익재단(삼성서울병원) 안지오텐신 전환효소 억제제의 부작용으로 발생하는마른기침을 저해하기 위한 철분을 포함하는 기침 저해조성물
CA2357982A1 (en) * 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
MXPA04006892A (es) * 2002-01-15 2004-10-15 Ranbaxy Lab Ltd Composiciones farmaceuticas estables que comprenden inhibidor(es) ace.
US6844361B2 (en) * 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
US20030175342A1 (en) * 2002-03-14 2003-09-18 Karl Kolter Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
BR0317028A (pt) * 2002-12-10 2005-10-25 Novartis Ag Combinação de um inibidor de dpp-iv e um composto de ppar-alfa
GB0301471D0 (en) * 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
AU2004275777A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
US7780985B2 (en) * 2005-07-12 2010-08-24 Accu-Break Technologies, Inc. Tablets having a printed separation mark to guide breaking
WO2005112898A1 (en) * 2004-05-21 2005-12-01 Accu-Break Pharmaceuticals, Inc. Pharmaceutical tablets having a relatively inactive segment
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US7713547B2 (en) 2004-05-21 2010-05-11 Accu-Break Pharmaceuticals, Inc. Method of administering a partial dose of a segmented pharmaceutical tablet
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
KR100593795B1 (ko) 2004-10-12 2006-06-30 대원제약주식회사 안정성이 개선된 라미프릴을 포함하는 경구투여용 제제
CA2586547A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
KR100714616B1 (ko) * 2005-06-23 2007-05-07 삼성전기주식회사 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기
BRPI0614417A2 (pt) * 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
EP1948136A1 (en) * 2005-11-07 2008-07-30 King Pharmaceuticals Research and Development, Inc. Compositions of stabilized ramipril in combination with another active agent
JP5259413B2 (ja) * 2005-11-18 2013-08-07 エーシーシーユー−ブレイク テクノロジーズ，インク． セグメント化した薬の剤形
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
RU2008145115A (ru) * 2006-04-19 2010-05-27 Тева Фармасьютикл Индастриес Лтд. (Il) Стабильные фармацевтические композиции производственных соединений 2-аза-бицикло[3.3.0]-октан-3-карбоновой кислоты
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US20110086092A1 (en) * 2006-08-08 2011-04-14 Accu-Break Technologies, Inc. Pharmacuetical tablets containing a plurality of active ingredients
JP2010511627A (ja) * 2006-11-30 2010-04-15 エーシーシーユー−ブレイク テクノロジーズ，インク． 分割可能な浸透性剤形及びその使用方法
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
SI2178513T1 (sl) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Tabletni sestavki vsebujoäśi atazanavir
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
DE602008005316D1 (de) * 2007-06-22 2011-04-14 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
PT2170292E (pt) * 2007-06-22 2014-03-06 Bristol Myers Squibb Holdings Ireland Composições de comprimido contendo atazanavir
EP2249815B1 (en) * 2008-01-25 2020-06-24 Laboratoires Majorelle Combinations of oral medicaments bonded by a wrapping
PE20110591A1 (es) 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
CN101843892B (zh) * 2010-05-18 2013-03-06 广州白云山制药股份有限公司广州白云山制药总厂 包括依那普利速释部分和非洛地平缓释部分的药物组合物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
SE429652B (sv) * 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3437917A1 (de) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
DE3704661A1 (de) * 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
TW197945B (sk) * 1990-11-27 1993-01-11 Hoechst Ag
DE4109134A1 (de) * 1991-03-20 1992-09-24 Knoll Ag Erzeugnisse, enthaltend verapamil und trandolapril
CA2070085A1 (en) * 1991-05-31 1992-12-01 Gerald P. Polli Ace inhibitor and calcium channel blocker for use in treating hypertension
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
PT804229E (pt) * 1995-03-16 2003-06-30 Pfizer Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica

Also Published As

Publication number Publication date
HK1001811A1 (en) 1998-07-10
DE726766T1 (de) 1997-01-30
DE69526640T2 (de) 2002-11-07
HU226894B1 (en) 2010-01-28
FI117616B (fi) 2006-12-29
IS1781B (is) 2001-10-01
KR100438133B1 (ko) 2004-09-04
IL115059A0 (en) 1996-01-19
NO308694B1 (no) 2000-10-16
ES2091173T1 (es) 1996-11-01
AU695865B2 (en) 1998-08-27
NZ292298A (en) 1998-02-26
CZ292224B6 (cs) 2003-08-13
CZ117396A3 (en) 1996-09-11
MY119489A (en) 2005-06-30
AU3402995A (en) 1996-03-27
DK0726766T3 (da) 2002-07-22
EP0726766B1 (en) 2002-05-08
JPH09504806A (ja) 1997-05-13
ATE217187T1 (de) 2002-05-15
EG24435A (en) 2009-06-25
CN1134665A (zh) 1996-10-30
FI961863A0 (fi) 1996-05-02
IS4337A (is) 1996-04-18
HUT76049A (en) 1997-06-30
PT726766E (pt) 2002-10-31
NZ329556A (en) 2000-07-28
MX9601586A (es) 1998-01-31
NO961726D0 (no) 1996-04-29
CA2174338A1 (en) 1996-03-14
NO961726L (no) 1996-04-29
FI961863A (fi) 1996-05-02
ES2091173T3 (es) 2002-12-01
RU2184563C2 (ru) 2002-07-10
TW483763B (en) 2002-04-21
WO1996007400A1 (en) 1996-03-14
SK283633B6 (sk) 2003-11-04
EP0726766A1 (en) 1996-08-21
DE69526640D1 (de) 2002-06-13
PL314084A1 (en) 1996-08-19
TR199501077A2 (tr) 1996-06-21
HU9601146D0 (en) 1996-07-29
EE03550B1 (et) 2001-12-17
SA95160287A (ar) 2005-12-03
SI0726766T1 (en) 2002-10-31
GR960300055T1 (en) 1996-10-31
CA2174338C (en) 2009-11-03
SA95160287B1 (ar) 2006-05-28
SK55896A3 (en) 1997-03-05
EE9600072A (et) 1996-12-16
PL186745B1 (pl) 2004-02-27
JP3776931B2 (ja) 2006-05-24
US6086919A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
IL115059A (en) Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
CY2191B1 (en) Use of a combination of an ace-inhibitor with a calcium antagonist in the treatment of proteinuria
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired